A new drug for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis:avacopan
ZHAO Jian-qun
JIN Hui-xin
WU Meng-ran
MA Yin-ling
PANG Guo-xun
WU Yu-pei
Abstract：Avacopan is an oral selective complement C5a receptor(C5aR)inhibitor that was approved by the FDA in October 2021 for the treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis in combination with standard therapy(glucocorticoids).Clinical studies have shown that avacopan can significantly reduce the dose of glucocorticoids used in the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis,reduce corticosteroid-related toxicity,and improve the prognosis of the disease.This article summarizes the mechanism of action,pharmacokinetics,clinical studies and safety of avacopan,aiming to provide references for clinical application.
Keywords：avacopanselective complement C5a receptor inhibitorsanti-neutrophil cytoplasm antibody-associated vasculitis
Publication Date：2024-09-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1752-1755 )